UroGen Pharma URGN Rightofuse Assets Operating And Finance Leases

Rightofuse Assets Operating And Finance Leases at other companies

Lantheus HoldingsLNTH

$32.24M-14.4%

TrimasTRS

$40.63M-14.4%

Bank of HawaiiBOH

$83.96M+4.0%

1st Source CorporationSRCE

$4.85M-4.5%

Turning Point BrandsTPB

$15.41M+42.8%

KEE

Keel Infrastructure Corp. Common StockKEEL

$13.23M-43.9%

Questions, answered.

What is UroGen Pharma's rightofuse assets operating and finance leases?

UroGen Pharma (URGN) reported rightofuse assets operating and finance leases of $7.94M in Q1 2026.

How has UroGen Pharma's rightofuse assets operating and finance leases changed year-over-year?

UroGen Pharma's rightofuse assets operating and finance leases increased by 67.1% year-over-year, from $4.75M to $7.94M.

What is the long-term trend for UroGen Pharma's rightofuse assets operating and finance leases?

Over 2 years (2023 to 2025), UroGen Pharma's rightofuse assets operating and finance leases has grown at a 125.0% compound annual growth rate (CAGR), from $1.67M to $8.46M.

What does rightofuse assets operating and finance leases mean?

This represents the capitalized value of the company's right to use leased assets, such as office space, laboratories, or specialized equipment, over the term of the lease. It reflects the asset side of lease accounting standards, balancing the corresponding lease liabilities on the balance sheet. Tracking this metric provides insight into the scale of the company's physical footprint and its reliance on leased infrastructure to support clinical and administrative operations.